Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:15:11 2024-04-25 am EDT			5-day change	1st Jan Change
12.94 ^USD	+1.57%		+31.25%	-30.86%

Apr. 01	Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans	CI
Mar. 29	Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Annovis Bio, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

July 28, 2021 at 03:52 pm EDT

Annovis Bio, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 2.534 million compared to USD 2.543 million a year ago. Net loss was USD 2.524 million compared to USD 2.309 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.34 a year ago. For the half year, operating loss was USD 5.763 million compared to USD 3.126 million a year ago. Net loss was USD 5.724 million compared to USD 2.751 million a year ago. Basic loss per share from continuing operations was USD 0.8 compared to USD 0.48 a year ago.

Latest news about Annovis Bio, Inc.

Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans	Apr. 01	CI
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Top Midday Gainers	Mar. 20	MT
Annovis Bio, Inc. Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease	Mar. 20	CI
Annovis Bio, Inc. announced that it expects to receive $1.025006 million in funding	Mar. 14	CI
An unknown buyer entered into an agreement to acquire 1.1% stake in Annovis Bio, Inc. for $1 million	Mar. 14	CI
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
Annovis Bio Shares Fall After Downgrade From Brookline Capital	Feb. 28	MT
Brookline Capital Downgrades Annovis Bio to Hold From Buy, $9 Price Target	Feb. 28	MT
Annovis Bio Completes Phase 2 Study of Alzheimer's Treatment Candidate	Feb. 14	MT
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease	Feb. 14	CI
Annovis Bio, Inc. Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company?s Portfolio	Jan. 30	CI
Certain Common Stock of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.	Jan. 29	CI
Certain Warrants of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.	Jan. 29	CI
Certain Stock Options of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.	Jan. 29	CI
Sector Update: Health Care Stocks Sliding Late Afternoon	Jan. 24	MT
Top Midday Decliners	Jan. 24	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	Jan. 24	MT
Annovis Bio Postpones Data Release for Parkinson's Treatment Trial -- Shares Fall	Jan. 24	MT
Annovis Bio, Inc. Refines Timeline for Parkinson's Phase III Study Data Announcement	Jan. 24	CI
Canaccord Genuity Initiates Annovis Bio at Buy With $36 Price Target	Dec. 29	MT
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase III Study of Buntanetap in Parkinson?s Disease	Dec. 05	CI
Sector Update: Health Care Stocks Ease in Late Afternoon	Nov. 27	MT
Sector Update: Health Care Stocks Softer Monday Afternoon	Nov. 27	MT
Sector Update: Health Care	Nov. 27	MT

Chart Annovis Bio, Inc.

Duration

Period

More charts

Company Profile

Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimerâs disease (AD), Parkinsonâs disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.74 USD

Average target price

35.4 USD

Spread / Average Target

+177.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANNOVIS BIO, INC.	-30.86%	140M
VERTEX PHARMACEUTICALS INCORPORATED	-3.15%	104B
REGENERON PHARMACEUTICALS, INC.	+0.18%	97.42B
ARGENX SE	+0.96%	22.2B
BIONTECH SE	-18.21%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.16%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+3.45%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.61%	11.66B

Bio Therapeutic Drugs